Innoviva(FRA) HVE

Market Cap€1.29B

Since IPON/A

5 YearN/A

1 YearN/A

1 MonthN/A

€17.90

-0.56%

-0.10Today

Innoviva Financials at a Glance

Market Cap

€1.29B

Revenue (TTM)

€389.16

Net Income (TTM)

€305.71

EPS (TTM)

€3.51

P/E Ratio

5.10

Dividend

€0.00

Beta (Volatility)

0.09 (Low)

Dividend

€0.00

Beta (Volatility)

0.09 (Low)

Price

€17.90

Volume

Open

€17.90

Price

€17.90

Volume

Open

€17.90

Previous Close

€17.90

Daily Range

€17.90 - €17.90

52-Week Range

€14.30 - €21.00

Estimated Earnings Date

N/A

Dividend

€0.00

Beta (Volatility)

0.09 (Low)

Price

€17.90

Volume

Open

€17.90

Previous Close

€17.90

Daily Range

€17.90 - €17.90

52-Week Range

€14.30 - €21.00

Estimated Earnings Date

N/A

HVE News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innoviva

Innoviva, Inc. is engaged in the development, commercialization, and financial management of biopharmaceuticals. Its portfolio includes Relvar Breo Ellipta, which is a once-daily combination medicine consisting of a long-acting beta2 agonist, vilanterol, and an inhaled corticosteroid, fluticasone furoate, and Anoro Ellipta, a once-daily medicine combining a long-acting muscarinic antagonist, umeclidinium bromide, LABA, VI. The company was founded by P. Roy Vagelos, Mathai Mammen, and George M. Whitesides in November 1996 and is headquartered in Burlingame, CA.

Industry

Pharmaceuticals

Sector

Health Care

Employees

159

CEO

Pavel Raifeld, CFA, MBA

Website

www.inva.com

HVE Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

36.23%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

19.61%

Dividend Yield

0.00%

Payout Ratio

N/A

Stock Overview

Market Cap

€1.29B

Shares Outstanding

72.25M

Volume

Avg. Volume

7.576

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Innoviva Performance Analysis

Innoviva annual revenue and year-over-year revenue growth by fiscal year
Fiscal year	Period end	Revenue	YoY growth
2022	2022-12-31	EUR 328,420,966	-4.3%
2023	2023-12-31	EUR 299,933,697	-8.7%
2024	2024-12-31	EUR 344,378,463	14.8%
2025	2025-12-31	EUR 376,693,519	9.4%

Innoviva annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal year	Period end	Diluted EPS	YoY growth
2022	2022-12-31	EUR 2.25	-7.2%
2023	2023-12-31	EUR 2.04	-9.6%
2024	2024-12-31	EUR 0.33	-83.6%
2025	2025-12-31	EUR 2.93	774.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name

Q2 2026YOY CHG

Revenue

€105.83

+1.2%

Gross Profit

€77.94

+1.1%

Gross Margin

73.64%

+0.9%

Market Cap

€1.29B

N/A

Market Cap/Employee

€9.38

N/A

Employees

159

N/A

Net Income

-€71.75

-1.3%

EBITDA

€52.47

+1.0%

Quarterly Fundamentals

Name

Q2 2026YOY CHG

Total Cash

€734.75

-5.7%

Total Debt

€235.86

+0.5%

Accounts Receivable

€96.75

+1.3%

Inventory

€34.08

+0.8%

Long Term Debt

€235.24

+0.9%

Short Term Debt

€0.62

+0.0%

Return on Assets

23.29%

+8.3%

Return on Invested Capital

18.00%

+0.9%

Free Cash Flow

€44.51

+1.3%

Operating Cash Flow

€44.89

+1.3%

Other Investments to Explore

People Also Watch

SymbolSymbol / CompanyCompanyPricePrice Chg

^GSPCS&P 500

^GSPCS&P 500$7,684.24-0.00%

^DJIDJI

^DJIDJI$53,254.61-0.01%

^IXICNASDAQ

^IXICNASDAQ$26,319.55-0.00%

BTCBitcoin

BTCBitcoin$78,890.00-0.00%

SPCXSPCX

SPCXSPCX$142.81+0.01%

AAPLAAPL

AAPLAAPL$315.25-0.01%

AMZNAMZN

AMZNAMZN$258.45-0.03%

Trending Stocks

SymbolSymbol / CompanyCompanyPricePrice Chg

PCGPG&E

PCGPG&E$13.27-0.20%

NVDANvidia

NVDANvidia$220.78+0.01%

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF

TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF$9.97+0.11%

CNHCNH Industrial

CNHCNH Industrial$11.83+0.01%

NUNu Holdings

NUNu Holdings$14.55+0.02%

BITOProShares Trust - ProShares Bitcoin ETF

BITOProShares Trust - ProShares Bitcoin ETF$10.63+0.02%

AALAmerican Airlines Group

AALAmerican Airlines Group$13.43-0.02%

Questions About HVE

What is the current price of Innoviva?

Innoviva is trading at €17.90 per share.

What is the 52-week range for Innoviva?

Over the past 52 weeks, Innoviva has traded between €14.30 and €21.00.

How much debt does Innoviva have?

As of the most recent reporting period, Innoviva reported total debt of €235.86M.

How much cash does Innoviva have on hand?

Innoviva reported €498.90M in cash and cash equivalents in its most recent financial results.

What is Innoviva’s dividend yield?

Innoviva does not currently have a dividend yield.

Innoviva(FRA) HVE

Innoviva Financials at a Glance

HVE News

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

About Innoviva

HVE Financials

Key Financial Metrics (TTM)

Stock Overview

Financials (TTM)

Innoviva Performance Analysis

Revenue Growth Rate

Earnings Per Share Growth Rate

Quarterly Performance

Quarterly Fundamentals

Other Investments to Explore

People Also Watch

Trending Stocks

Questions About HVE

What is the current price of Innoviva?

What is the 52-week range for Innoviva?

How much debt does Innoviva have?

How much cash does Innoviva have on hand?

What is Innoviva’s dividend yield?

Premium Investing Services